Establishing an accurate neurological diagnosis in children presenting with acute demyelinating events remains a major clinical challenge. The role of viral pathogens, especially EBV in paediatric MS, offers critical insights into underlying disease biology. While adult studies confirm an undeniable link between Epstein-Barr virus and multiple sclerosis, data in younger cohorts have historically remained less definitive. Recent investigations clarify how distinct viral profiles separate paediatric multiple sclerosis from other inflammatory conditions. Consequently, evaluating pathogen-specific humoral responses provides pediatricians and neurologists with robust tools to navigate complex differential diagnoses effectively.

Unraveling the Role of EBV in Paediatric MS

Epidemiological evidence has long suggested that environmental triggers initiate central nervous system autoimmunity in genetically predisposed individuals. Recent research demonstrates that remote Epstein-Barr virus infection represents an almost universal antecedent in early-onset central demyelination. Specifically, investigators examining Dutch multicentre cohorts identified prior EBV exposure in 100% of children diagnosed with multiple sclerosis. In contrast, healthy pediatric control groups and patients with non-MS neuroinflammatory diseases display significantly lower viral seroprevalence rates.

Moreover, this biological disparity challenges previous assumptions that paediatric cases might follow an EBV-independent pathogenic pathway. Because young children experience fewer lifetime viral exposures, establishing a complete seropositivity rate in paediatric MS highlights the obligate nature of this herpesvirus in triggering the disease. Furthermore, researchers observed that humoral responses against Epstein-Barr nuclear antigen 1 and viral capsid antigen were dramatically heightened. Therefore, evaluating EBV in paediatric MS reinforces the concept that abnormal immune responses toward this specific virus drive neuroinflammatory cascade initiation.

Divergent Viral Serology in MOGAD and ADS

Acquired demyelinating syndromes encompass a heterogeneous spectrum of childhood neurological disorders. These conditions include myelin-oligodendrocyte glycoprotein antibody-associated disease, acute disseminated encephalomyelitis, and transverse myelitis. Clinicians often find it difficult to differentiate these entities at disease onset because symptoms overlap considerably. However, viral serology profiles present a stark divergence across these patient cohorts.

While every child with multiple sclerosis exhibited remote EBV exposure, only 50% of children with MOGAD and 67% with other demyelinating syndromes tested positive. Furthermore, this statistically significant difference confirms that MOGAD possesses a pathobiology distinct from classic multiple sclerosis. Interestingly, human herpesvirus 6 seroprevalence remained uniformly ubiquitous across all groups, exceeding 85% in each cohort. Consequently, HHV-6 appears to reflect normal background population exposure rather than an etiology-specific catalyst. In contrast, cytomegalovirus seropositivity was notably higher in children with MOGAD than in those with multiple sclerosis, despite the MOGAD cohort presenting at a younger median age. Thus, distinct viral interactions characterize these demyelinating phenotypes.

Diagnostic Biomarkers and EBNA-1 Antibody Titres

Differentiating true paediatric multiple sclerosis from monophasic or antibody-mediated demyelination dictates urgent therapeutic decisions. Quantitative antibody assessment serves as a valuable adjunct when imaging and clinical presentations appear ambiguous. Specifically, titres of anti-EBNA-1 IgG antibodies reach exceptionally high levels in paediatric multiple sclerosis cases compared to other demyelinating conditions.

Additionally, viral capsid antigen antibody concentrations show similar robust elevations in multiple sclerosis patients. Clinicians can utilize these heightened serological signals alongside conventional biomarkers, such as oligoclonal bands and myelin oligodendrocyte glycoprotein autoantibodies. While isolated seropositivity indicates past infection, persistent and pronounced humoral elevation signals altered immunological tolerance. Consequently, incorporating quantitative EBV serology into initial diagnostic workups assists clinicians in ruling out alternative diagnoses earlier. This immunological discrimination prevents unnecessary delays in initiating disease-modifying therapies, thereby preserving precious neurological function in developing children.

Clinical Correlations and Disease Trajectory Findings

Although serological data provide profound diagnostic utility, their capacity to predict ongoing clinical activity remains nuanced. Investigators closely analyzed whether magnitude of anti-EBNA-1 titres correlated with disease severity markers. Surprisingly, elevated antibody levels showed no direct correlation with annualized relapse rates in children with multiple sclerosis.

Furthermore, researchers observed no statistically significant relationship between baseline antibody levels and Expanded Disability Status Scale scores. Similarly, neuroimaging parameters, such as the accumulation of hypointense T1 black holes indicating permanent axonal injury, showed no quantitative connection to viral antibody titres. These findings suggest that while EBV acts as an essential permissive factor for disease onset, other biological mechanisms drive ongoing neurodegeneration and acute relapses. Therefore, clinicians must avoid using antibody titres as continuous surrogates for monitoring therapeutic response or predicting short-term clinical trajectories. Routine neuroimaging and structured clinical examinations remain the gold standards for monitoring active central nervous system inflammation.

Distinguishing Demyelinating Syndromes in Clinical Practice

Navigating childhood demyelinating disorders requires a systematic and structured clinical approach. Pediatric neurologists must distinguish multiple sclerosis from MOGAD rapidly, as therapeutic approaches differ substantially. For instance, while pediatric MS requires early escalation to high-efficacy disease-modifying therapies, MOGAD management emphasizes acute immunosuppression and tailored steroid tapers.

Accordingly, serological evaluation of EBV status provides an objective filter. A child presenting with an acute demyelinating syndrome who remains entirely seronegative for EBV is highly unlikely to have multiple sclerosis. In such scenarios, clinicians should focus testing on MOG autoantibodies, aquaporin-4 antibodies, and alternative inflammatory etiologies. Moreover, documenting older age at presentation alongside marked EBNA-1 elevation substantially increases the pre-test probability of multiple sclerosis. By synthesizing viral serology, neuroimaging patterns, and cerebrospinal fluid parameters, clinicians build an accurate, comprehensive diagnostic foundation that minimizes misdiagnosis and avoids inappropriate chronic therapies.

Future Therapeutic Directions and Preventive Strategies

The definitive link between remote viral exposure and early-onset demyelinating disease unlocks unprecedented avenues for prevention and targeted intervention. As research clarifies how EBV perturbs adaptive immune tolerance, developing prophylactic EBV vaccines emerges as an attractive public health strategy. Preventing primary childhood or adolescent EBV infection could dramatically decrease global paediatric multiple sclerosis incidence.

Additionally, modern therapeutic strategies are actively exploring antiviral agents and cellular therapies targeting EBV-infected B lymphocytes. Because latent EBV resides predominantly inside memory B cells, treatments that deplete these cellular reservoirs may alter disease progression at its biological origin. Furthermore, cross-reactive autoantibodies generated through molecular mimicry between EBNA-1 and central nervous system proteins present novel targets for selective immunotherapy. As our understanding of pathogen-immune interactions advances, therapeutic paradigms will shift from broad immunosuppression toward precise, mechanism-targeted disease elimination.

How does EBV serology differentiate paediatric MS from MOGAD?

Every child diagnosed with paediatric multiple sclerosis demonstrated prior exposure to Epstein-Barr virus, particularly with elevated EBNA-1 titres. In contrast, only half of children with MOGAD showed remote EBV exposure. Consequently, testing for EBV antibodies provides clinicians with an effective immunological discriminator when clinical and neuroimaging presentations overlap.

Does a higher EBNA-1 antibody titre correlate with worse disability in paediatric MS?

Although EBNA-1 levels remain markedly elevated in paediatric multiple sclerosis, current evidence indicates that antibody titres do not correlate directly with clinical severity. Specifically, researchers observed no significant association between antibody concentrations and annualized relapse rates, Expanded Disability Status Scale scores, or the accumulation of baseline MRI black holes.

What role does cytomegalovirus play in children with acquired demyelinating syndromes?

Cytomegalovirus infection appears more frequently in children with MOGAD than in those with paediatric multiple sclerosis, despite the younger median age of MOGAD onset. While CMV does not cause demyelination directly, its presence highlights distinct immunological profiles and suggests that alternate environmental triggers drive different acquired central nervous system syndromes.

Disclaimer: This content is for informational and educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Molenaar S et al. Strong association with remote EBV infection in children with MS as opposed to other acquired demyelinating disorders. J Neurol Neurosurg Psychiatry. 2025 Sep 12. doi: 10.1136/jnnp-2024-335689. PMID: 40102037.

Al-Jaberi R, et al. Epstein-Barr Virus Strongly Associates With Pediatric Multiple Sclerosis, But Not Myelin Oligodendrocyte Glycoprotein-Antibody-Associated Disease. Ann Neurol. 2024;95(4):700-705.

Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296-301.